SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
QQQ   270.00 (-3.49%)
AAPL   140.42 (-3.44%)
MSFT   234.85 (-4.84%)
META   133.08 (-4.31%)
GOOGL   98.83 (-2.55%)
AMZN   114.54 (-4.79%)
TSLA   224.69 (-5.64%)
NVDA   122.41 (-6.77%)
NIO   13.72 (-7.11%)
BABA   81.33 (-3.55%)
AMD   59.98 (-11.60%)
T   15.05 (-1.76%)
MU   53.52 (-2.01%)
CGC   2.85 (-24.00%)
F   12.16 (-1.62%)
GE   64.51 (-2.58%)
DIS   97.11 (-2.93%)
AMC   6.51 (-8.57%)
PYPL   90.41 (-4.25%)
PFE   42.36 (-1.69%)
NFLX   229.29 (-4.47%)
QQQ   270.00 (-3.49%)
AAPL   140.42 (-3.44%)
MSFT   234.85 (-4.84%)
META   133.08 (-4.31%)
GOOGL   98.83 (-2.55%)
AMZN   114.54 (-4.79%)
TSLA   224.69 (-5.64%)
NVDA   122.41 (-6.77%)
NIO   13.72 (-7.11%)
BABA   81.33 (-3.55%)
AMD   59.98 (-11.60%)
T   15.05 (-1.76%)
MU   53.52 (-2.01%)
CGC   2.85 (-24.00%)
F   12.16 (-1.62%)
GE   64.51 (-2.58%)
DIS   97.11 (-2.93%)
AMC   6.51 (-8.57%)
PYPL   90.41 (-4.25%)
PFE   42.36 (-1.69%)
NFLX   229.29 (-4.47%)
QQQ   270.00 (-3.49%)
AAPL   140.42 (-3.44%)
MSFT   234.85 (-4.84%)
META   133.08 (-4.31%)
GOOGL   98.83 (-2.55%)
AMZN   114.54 (-4.79%)
TSLA   224.69 (-5.64%)
NVDA   122.41 (-6.77%)
NIO   13.72 (-7.11%)
BABA   81.33 (-3.55%)
AMD   59.98 (-11.60%)
T   15.05 (-1.76%)
MU   53.52 (-2.01%)
CGC   2.85 (-24.00%)
F   12.16 (-1.62%)
GE   64.51 (-2.58%)
DIS   97.11 (-2.93%)
AMC   6.51 (-8.57%)
PYPL   90.41 (-4.25%)
PFE   42.36 (-1.69%)
NFLX   229.29 (-4.47%)
QQQ   270.00 (-3.49%)
AAPL   140.42 (-3.44%)
MSFT   234.85 (-4.84%)
META   133.08 (-4.31%)
GOOGL   98.83 (-2.55%)
AMZN   114.54 (-4.79%)
TSLA   224.69 (-5.64%)
NVDA   122.41 (-6.77%)
NIO   13.72 (-7.11%)
BABA   81.33 (-3.55%)
AMD   59.98 (-11.60%)
T   15.05 (-1.76%)
MU   53.52 (-2.01%)
CGC   2.85 (-24.00%)
F   12.16 (-1.62%)
GE   64.51 (-2.58%)
DIS   97.11 (-2.93%)
AMC   6.51 (-8.57%)
PYPL   90.41 (-4.25%)
PFE   42.36 (-1.69%)
NFLX   229.29 (-4.47%)
NASDAQ:BYSI

BeyondSpring - BYSI Stock Forecast, Price & News

$1.01
-0.04 (-3.81%)
(As of 10/7/2022 01:45 PM ET)
Add
Compare
Today's Range
$0.98
▼
$1.06
50-Day Range
$0.94
▼
$1.67
52-Week Range
$0.92
▼
$17.98
Volume
205 shs
Average Volume
122,714 shs
Market Capitalization
$39.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67

BeyondSpring MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,055.1% Upside
$11.67 Price Target
Short Interest
Bearish
11.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of BeyondSpring in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.18) to ($1.75) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

1004th out of 1,075 stocks

Pharmaceutical Preparations Industry

500th out of 537 stocks

See Top Rated MarketRank™ Stocks Here
BYSI stock logo

About BeyondSpring (NASDAQ:BYSI) Stock

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Receive BYSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.

BYSI Stock News Headlines

October 3, 2022 | americanbankingnews.com
Short Interest in BeyondSpring Inc. (NASDAQ:BYSI) Drops By 5.9%
September 29, 2022 | uk.finance.yahoo.com
BeyondSpring Inc. (BYSI)
September 13, 2022 | finance.yahoo.com
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022 - Yahoo Finance
September 13, 2022 | finance.yahoo.com
BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours
September 13, 2022 | globenewswire.com
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022 - GlobeNewswire
September 13, 2022 | finance.yahoo.com
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
September 8, 2022 | seekingalpha.com
BeyondSpring Q2 2022 Earnings Preview - Seeking Alpha
August 29, 2022 | finance.yahoo.com
BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients - Yahoo Finance
August 29, 2022 | finance.yahoo.com
BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients
August 29, 2022 | globenewswire.com
BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting - GlobeNewswire
August 29, 2022 | finance.yahoo.com
BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting
August 25, 2022 | globenewswire.com
Marine Pharmaceuticals Market exhibiting a CAGR of 8.59% and is expected to reach USD 47218.50 million by 2029 - GlobeNewswire
August 18, 2022 | reuters.com
BYSI.O - Beyondspring Inc | Stock Price & Latest News | Reuters
August 15, 2022 | nasdaq.com
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
August 12, 2022 | nasdaq.com
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
August 11, 2022 | nasdaq.com
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq
July 6, 2022 | finance.yahoo.com
Vascular Disrupting Agents Market worth $2.25 billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance
June 30, 2022 | businesswire.com
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop - Business Wire
June 28, 2022 | streetinsider.com
Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer - StreetInsider.com
June 23, 2022 | nasdaq.com
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
June 21, 2022 | finance.yahoo.com
The Worldwide Neutropenia Industry is Projected to Reach $5.4 Billion by 2027 - Yahoo Finance
June 20, 2022 | globenewswire.com
The Worldwide Neutropenia Industry is Projected to Reach $5.4 Billion by 2027 - GlobeNewswire
June 10, 2022 | benzinga.com
Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring? - Benzinga - Benzinga
June 7, 2022 | nasdaq.com
HealthEquity (HQY) Q1 Earnings Miss Estimates - Nasdaq
May 27, 2022 | globenewswire.com
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting - GlobeNewswire
See More Headlines
Receive BYSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.

BYSI Company Calendar

Last Earnings
12/29/2021
Today
10/07/2022
Next Earnings (Estimated)
12/29/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BYSI
CUSIP
N/A
CIK
1677940
Web
www.beyondspringpharma.com
Phone
(646) 305-6387
Fax
1-646-882-4228
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.67
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,055.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.35 million
Price / Sales
29.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
1.87

Miscellaneous

Outstanding Shares
38,930,000
Free Float
N/A
Market Cap
$39.32 million
Optionable
Not Optionable
Beta
1.11

Key Executives

  • Dr. Lan Huang (Age 51)
    Co-Founder, Chairman & CEO
  • Dr. G. Kenneth Lloyd (Age 78)
    Chief Scientific Officer
  • Dr. Ramon W. Mohanlal (Age 64)
    Exec. VP of R&D, Chief Medical Officer and Director
  • Mr. Linqing Jia
    Co-Founder
  • Stephen Kilmer
    Head of Investor Relations
  • Mr. Gregg Russo
    Sr. VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BYSI Stock - Frequently Asked Questions

Should I buy or sell BeyondSpring stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BYSI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BYSI, but not buy additional shares or sell existing shares.
View BYSI analyst ratings or view top-rated stocks.

What is BeyondSpring's stock price forecast for 2022?

5 Wall Street analysts have issued 12-month price objectives for BeyondSpring's stock. Their BYSI share price forecasts range from $5.00 to $25.00. On average, they predict the company's stock price to reach $11.67 in the next year. This suggests a possible upside of 1,011.1% from the stock's current price.
View analysts price targets for BYSI or view top-rated stocks among Wall Street analysts.

How have BYSI shares performed in 2022?

BeyondSpring's stock was trading at $4.53 at the start of the year. Since then, BYSI shares have decreased by 76.8% and is now trading at $1.05.
View the best growth stocks for 2022 here.

When is BeyondSpring's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 29th 2022.
View our BYSI earnings forecast.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings data on Wednesday, December, 29th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.11. The company earned $0.34 million during the quarter, compared to analysts' expectations of $0.34 million.

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

How do I buy shares of BeyondSpring?

Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $1.05.

How much money does BeyondSpring make?

BeyondSpring (NASDAQ:BYSI) has a market capitalization of $40.88 million and generates $1.35 million in revenue each year. The company earns $-64,180,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The official website for the company is www.beyondspringpharma.com. The company can be reached via phone at (646) 305-6387, via email at general@beyondspringpharma.com, or via fax at 1-646-882-4228.

This page (NASDAQ:BYSI) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.